List view / Grid view
3 September 2013 | By Novartis
Ilaris® is the first interleukin-1 beta (IL-1 beta) inhibitor for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) and is the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection[1]...
2 September 2013 | By Novartis
New analysis of RELAX-AHF published in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress[1],[2]...
26 August 2013 | By Novartis
Novartis has invited 60 selected students from leading international universities in 21 countries to its headquarters in Switzerland for the International Biotechnology Leadership Camp...
20 August 2013 | By Novartis
Novartis announced that the US FDA has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM)...
15 August 2013 | By Novartis
The Australian Therapeutic Goods Administration (TGA) has added Bexsero® to the Australian Register of Therapeutic Goods (ARTG)...
8 August 2013 | By Novartis
"At Novartis, we believe that everyone should have access to early screening programs and innovative therapies..."
7 August 2013 | By Novartis
Everolimus did not show survival benefit for patients with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafinib...
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
1 August 2013 | By Novartis
Novartis announced that the US FDA approved Menveo®...
26 July 2013 | By Novartis
Novartis announced that the CHMP of the EMA has adopted a positive opinion for the use of Ilaris® (canakinumab)...
26 July 2013 | By Novartis
Novartis announced that the EMA's CHMP has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®...
24 July 2013 | By Novartis
Following JCVI interim recommendation on Novartis Bexsero® vaccine...
17 July 2013 | By Novartis
The Novartis Board of Directors announced a final agreement with its former Chairman, Dr. Daniel Vasella.
8 July 2013 | By Novartis
All primary & secondary endpoints were met...
8 July 2013 | By Novartis
Novartis has entered into a development and licensing agreement with Biological E Limited...
